Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...
Investor's Business Daily on MSN12h
Dexcom Stock Makes A Recovery After Its Fourth-Quarter FumbleDexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.
Informatica shares are down 49% in the last 12 months, compared with the S&P 500 index's SPX gain of 22.4%. Shares of rival International Business Machines Corp. (IBM) are up 39.3% in the last 12 ...
The persistent rise in US equities is helping promote a view that the relationships of old for stocks and traditional measures for value-oriented investing strategies no longer apply.
Choreo LLC increased its stake in FactSet Research Systems Inc. (NYSE:FDS – Free Report) by 12.0% in the fourth quarter, ...
The report, entitled Unlocking Operational Excellence in Fund Administration through AI, is based on insights from in-depth ...
Shares of FactSet Research Systems Inc. FDS rose 1.14% to $459.39 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.04% to 6, ...
CBRE Group posted strong fourth-quarter earnings for 2024, surpassing analyst expectations and demonstrating solid segment performance.
AI is still a nascent part of Moody's business, but the early indicators point to success for company. That makes the stock a terrific opportunity to buy hand over fist. Investors with a long-run ...
FactSet’s private markets data strategy, the relationship between risk and performance on the buy side and fixed income track record ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback